GSK Gets 2nd Chance To Argue Preemption In Zofran MDL
By Chris Villani · July 10, 2019, 5:24 PM EDT
A Massachusetts federal judge on Wednesday said GlaxoSmithKline will get another chance to argue that claims its anti-nausea drug Zofran caused birth defects are federally preempted, adding he will seek guidance...
To view the full article, register now.